InnoCare Pharma Limited
INCPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.20 | 0.30 | -5.38 | -0.05 |
| FCF Yield | -0.04% | -0.45% | 0.10% | -0.10% |
| EV / EBITDA | -1,903.47 | -256.99 | -11,365.92 | -275.59 |
| Quality | ||||
| ROIC | -1.05% | -0.59% | 0.17% | -1.94% |
| Gross Margin | 87.38% | 88.39% | 90.54% | 87.03% |
| Cash Conversion Ratio | 0.02 | 2.46 | 3.15 | 0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.23% | 20.62% | 20.88% | -10.03% |
| Free Cash Flow Growth | 98.39% | -409.20% | 205.31% | 41.00% |
| Safety | ||||
| Net Debt / EBITDA | 274.23 | 62.21 | 1,676.45 | 40.76 |
| Interest Coverage | -5.77 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 0.35 | 0.37 | 0.42 |
| Cash Conversion Cycle | 61.91 | -32.69 | -85.38 | 34.15 |